Phase II safety and tolerability study of Radium-223 (R223) in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CTRIAL-IE (ICORG) 13-21
| Autor: | Raymond S. McDermott, Imelda Parker, Paul J. Kelly, Stephen P. Finn, John Greene, Olwyn Deignan, Pierre Thirion, Ausra Teiserskiene, John McCaffrey, Alison Bowes, John Feeney |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Radium-223
Oncology Cancer Research medicine.medical_specialty Standard of care business.industry 030232 urology & nephrology Castration resistant medicine.disease 03 medical and health sciences Prostate cancer chemistry.chemical_compound 0302 clinical medicine chemistry 030220 oncology & carcinogenesis Tolerability Study Internal medicine medicine Enzalutamide In patient business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 36:5050-5050 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2018.36.15_suppl.5050 |
| Popis: | 5050Background: R223 and ENZA are standard of care agents in the treatment of patients (pts) with mCRPC. The combination of R223 and ENZA is of interest due to differing modes of action and non-ove... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|